Results 81 to 90 of about 57,515 (223)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Negative Prognostic Impact of the Coexpression of Epidermal Growth Factor Receptor and c-erbB-2 in Locally Advanced Cervical Cancer

, 2009
Objective: The objective was to determine the impact of the coexpression of epidermal growth factor receptor (EGFR) and tumor marker c-erbB-2 on disease-free survival (DFS) and pelvic relapse-free survival (PRFS) in patients with locally advanced ...
Alonso, Lorenzo, Ballestín Carcavilla, Claudio, Alba, Emilio, De-la-Cruz, Javier, Mendiola Fernández, Dionisio César, García-Martín, Rosa, Pérez-Regadera Gómez, José Fermín, Lora Pablos, David, Sánchez-Muñoz, Alfonso, Lanzós González, Eduardo   +9 more
core   +1 more source

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Breast Cancer Research, 2017
Background The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur ...
Sinead Toomey, Alexander J. Eustace, Joanna Fay, Katherine M. Sheehan, Aoife Carr, Malgorzata Milewska, Stephen F. Madden, Ausra Teiserskiene, Elaine W. Kay, Norma O’Donovan, William Gallagher, Liam Grogan, Oscar Breathnach, Janice Walshe, Catherine Kelly, Brian Moulton, M. John Kennedy, Guiseppe Gullo, Arnold D. Hill, Colm Power, Deirdre Duke, Niamh Hambly, John Crown, Bryan T. Hennessy   +23 more
doaj   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers

Therapeutic Advances in Medical Oncology, 2018
Background: The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations.
Malgorzata Milewska, Mattia Cremona, Clare Morgan, John O’Shea, Aoife Carr, Sri HariKrishna Vellanki, Ann M. Hopkins, Sinead Toomey, Stephen F. Madden, Bryan T. Hennessy, Alex J. Eustace   +10 more
doaj   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI‐Platinum Therapy (WJOG14120L)

Cancer Science, EarlyView.
WJOG14120L NESSIE evaluated cisplatin, gemcitabine, and necitumumab (CGN) as second‐line therapy after ICI‐based treatment in 46 patients with advanced squamous NSCLC. ORR was 26.1%, DCR 87.0%, and median PFS 4.4 months. Although the predefined ORR threshold was not met, CGN showed modest antitumor activity with manageable toxicity.
Hiroshige Yoshioka, Keita Mori, Nobuhisa Ishikawa, Hiroaki Kanemura, Koichi Azuma, Yukihiro Toi, Hiroshi Handa, Yosuke Tamura, Hiroaki Akamatsu, Haruko Daga, Masafumi Yamaguchi, Teppei Yamaguchi, Yuki Sato, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Takayasu Kurata   +15 more
wiley   +1 more source

Periodontitis and metabolic dysfunction‐associated steatotic liver disease

Periodontology 2000, EarlyView.
Abstract Objective Periodontitis is a chronic inflammatory disease with systemic effects that extend beyond the oral cavity and contribute to systemic immune and metabolic dysregulation. Chronic liver diseases, particularly metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive phenotypes, have emerged as major global ...
Rafael Scaf de Molon, Erica Dorigatti de Avila, Davi da Silva Barbirato, Mariana Fampa Fogacci, Jamil Awad Shibli, Anton Sculean, Alpdogan Kantarci   +6 more
wiley   +1 more source

Maternal obesity during lactation as a hypertensive cardiovascular risk factor in the offspring

Experimental Physiology, EarlyView.
Abstract Maternal obesity is a major public health concern, with growing evidence supporting its role in the developmental programming of cardiometabolic disease. Although prenatal mechanisms have been investigated extensively, the contribution of lactation as a postnatal window of cardiovascular (CV) programming remains insufficiently understood ...
Gabriela Arenas, Cristián A. Amador, Susana Contreras‐Duarte   +2 more
wiley   +1 more source

Expression of the ErbB-neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma

, 1998
The four receptor tyrosine kinase I receptors, ErbB-1, ErbB-2, ErbB-3, and ErbB-4, which have been implicated in the development of a variety of normal and malignant tissues, are activated through ligand mediated homo- and heterodimerization.
Lunec J, Gilbertson RJ, Clifford SC, MacMeekin W, Pearson ADJ, Perry RH, Wright C, Kelly P   +7 more
core   +4 more sources